Sequential CD19 and BCMA‐specific CAR T‐cell treatment elicits sustained remission of relapsed and/or refractory myeloma

The low rate of durable response against relapsed and/or refractory multiple myeloma (RRMM) in recent studies indicates that chimeric antigen receptor T‐cell (CART) treatment is yet to be optimized. This study aims to investigate the safety and efficacy of sequential infusion of CD19‐CART and B‐cell...

Popoln opis

Shranjeno v:
Bibliografske podrobnosti
izdano v:Cancer Med
Main Authors: Yan, Lingzhi, Qu, Su, Shang, Jingjing, Shi, Xiaolan, Kang, Liqing, Xu, Nan, Zhu, Mingqing, Zhou, Jin, Jin, Song, Yao, Weiqin, Yao, Ying, Chen, Guanghua, Chang, Huirong, Zhu, Xiaming, Yu, Lei, Wu, Depei, Fu, Chengcheng
Format: Artigo
Jezik:Inglês
Izdano: John Wiley and Sons Inc. 2020
Teme:
Clinical Cancer Research
Online dostop:https://ncbi.nlm.nih.gov/pmc/articles/PMC7877347/
https://ncbi.nlm.nih.gov/pubmed/33356013
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/cam4.3624
Oznake: Označite
Brez oznak, prvi označite!

Podobne knjige/članki